Apr 9 2024
Healthcare
Recent Research
Uniphar, Focus on the target
Apr 3 2024
hVIVO, Trading update
Jan 30 2024
Meet your Healthcare Research team
hVIVO
FY2023 results
hVIVO made significant progress in 2023 with multiple challenge contracts signed and a record number of volunteers inoculated. Top-line growth of 16% drove margin expansion and led to...
Uniphar
Focus on the target
We believe that the headwinds that held back Uniphar’s stock in 2022-2023 are now in the past. The outlook is far more positive. We estimate that achieving its medium-term EBITDA...
CVS Group
CMA provisionally launching a formal market investigation
The Competition and Markets Authority (CMA) announced yesterday (March 12th) that its initial review into the vets market has identified multiple concerns. It has provisionally launched...
CVS Group
H1 2024 results reflect another period of good growth
Following the trading statement on January 25th, CVS has reported interim results to December 31st that reflect strong like-for-like top-line growth and an EBITDA margin of 19.1%, both...
Uniphar
FY2023 results reflect strong organic gross profit growth
Uniphar’s FY2023 results reflect strong organic growth in gross profits of 5.6% year-on-year (yoy). Adjusted EBITDA expanded 18% yoy. Higher interest costs and depreciation charges...
hVIVO
Trading update
hVIVO’s trading update for the year ending December 31st reflects stronger than expected results driven by strong margins. The outlook for 2024 is very positive with 90% revenue...
Uniphar
Trading statement
Uniphar’s trading statement to the end December 31st highlights a strong year of operating results. We are maintaining our forecasts. The outlook for 2024 is very positive and we...
Malin Corporation
CG Oncology IPO drives NAV growth
Malin has announced that one of its investments, CG Oncology, will list on the NASDAQ today following its initial public offering (IPO). Based on pricing, the value of the group’s existing...
CVS Group
H1 2024 trading statement
CVS has reported strong revenue growth of 11.4% year-on-year (yoy) and an EBITDA margin of 19.0% in its trading statement for H1 2024 to December 31st. These figures are in line with...
CVS Group
Trading update ahead of AGM
CVS has issued a trading statement, covering the first four months of its H1 2024 to end-October, ahead of its AGM today. Revenue growth and the EBITDA margin are in line with...
